Home Newsfeeds Baird Maintains Outperform on First Solar, Raises Price Target to $208

Baird Maintains Outperform on First Solar, Raises Price Target to $208

Baird analyst Ben Kallo maintains First Solar (NASDAQ:FSLR) with a Outperform and raises the price target from $180 to $208.

byBenzinga Newsdesk

March 1, 2023

1 minute read

Baird analyst Ben Kallo maintains First Solar (NASDAQ:FSLR) with a Outperform and raises the price target from $180 to $208.

How To Earn $500 A Month From TD Synnex Stock After Q3 Results

By Priya Nigam

September 27, 8:42 AM

TD Synnex Corp (NYSE: SNX) recently reported mixed results for its third quarter.

SNX

Here’s How Much You Would Have Made Owning Automatic Data Processing Stock In The Last 15 Years

By Benzinga Insights

November 1, 12:00 PM

Automatic Data Processing (NASDAQ:ADP) has outperformed the market over the past 15 years by 1.97% on an annualized…

ADP

New Study Published In The American Journal Of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated With Cholestatic Liver Disease

By Michael Horton

December 8, 7:04 PM

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, is pleased to share

ICPT

CytoSorbents Awarded An ~$4.3M Contract By The U.S. Department Of Defense To Develop HemoDefend-BGA For Freeze-Dried Universal Plasma

By Benzinga Newsdesk

October 6, 7:02 AM

CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded

CTSO

Baird Maintains Outperform on First Solar, Raises Price Target to $208

Related Posts

How To Earn $500 A Month From TD Synnex Stock After Q3 Results

Here’s How Much You Would Have Made Owning Automatic Data Processing Stock In The Last 15 Years

New Study Published In The American Journal Of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated With Cholestatic Liver Disease

CytoSorbents Awarded An ~$4.3M Contract By The U.S. Department Of Defense To Develop HemoDefend-BGA For Freeze-Dried Universal Plasma